|Drug Patent Number||Company||Drug Patent Title||Drug Patent Expiry||Activity Alert|
|These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US8071577||BAYER HLTHCARE||Multi-phase contraceptive preparation based on a natural estrogen|| |
(2 years from now)
|US8153616||BAYER HLTHCARE||Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same|| |
(4 years from now)
Natazia is owned by Bayer Hlthcare.
Natazia contains Dienogest; Estradiol Valerate.
Natazia has a total of 2 drug patents out of which 0 drug patents have expired.
Natazia was authorised for market use on 06 May, 2010.
Natazia is available in tablet;oral dosage forms.
Natazia can be used as treatment of heavy menstrual bleeding in women without organic pathology who choose to use an oral contraceptive as their method of contraception, prevention of pregnancy.
The generics of Natazia are possible to be released after 30 January, 2028.
Market Authorisation Date: 06 May, 2010
Treatment: Prevention of pregnancy; Treatment of heavy menstrual bleeding in women without organic pathology who choose to use an oral contraceptive as their method of contraception
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic